文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

血管加压素V1a受体拮抗剂改善男性孤独症谱系障碍患者适应行为的2期临床试验

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder.
PubMed 文献 · Sci Transl Med · 2019-05-01

这项2期VANILLA临床试验在223名智商≥70的男性孤独症谱系障碍(ASD)患者中评估口服选择性血管加压素V1a受体拮抗剂巴洛伐普坦(balovaptan)的疗效与安全性。患者随机接受安慰剂(n=75)或巴洛伐普坦1.5 mg(n=32)、4 mg(n=77)、10 mg(n=39)每日治疗12周。主要疗效终点(社交反应量表第2版)未显示巴洛伐普坦较安慰剂显著改变;但4 mg和10 mg组在Vineland-II适应行为量表复合评分上较安慰剂出现剂量依赖且有临床意义的改善,主要源于社交化和沟通分项的改善。巴洛伐普坦各剂量耐受良好,未发现药物相关安全性问题。

要点

  • 主要终点社交反应量表第2版未显示巴洛伐普坦较安慰剂显著改善。
  • 巴洛伐普坦4 mg和10 mg组Vineland-II适应行为量表复合评分较安慰剂有剂量依赖的临床意义改善。
  • 改善主要来自Vineland-II社交化和沟通分项;各剂量耐受良好。

核心结论

  • 巴洛伐普坦4 mg和10 mg治疗12周在Vineland-II适应行为量表复合评分上较安慰剂显示剂量依赖且有临床意义的改善,主要源于社交化和沟通分项。
  • 主要疗效终点社交反应量表第2版未显示巴洛伐普坦较安慰剂显著改变。
  • 巴洛伐普坦各剂量耐受良好,未发现药物相关安全性问题。
  • 结果支持进一步研究巴洛伐普坦作为ASD社交和沟通缺陷的潜在治疗。

研究设计与样本

  • 2期VANILLA临床试验,纳入223名智商≥70的男性ASD患者。
  • 随机分组:安慰剂(n=75)、巴洛伐普坦1.5 mg(n=32)、4 mg(n=77)、10 mg(n=39),每日口服治疗12周。

主要发现

  • 主要疗效终点(社交反应量表第2版)12周时巴洛伐普坦较安慰剂无显著变化。
  • Vineland-II适应行为量表复合评分:巴洛伐普坦4 mg和10 mg组较安慰剂出现剂量依赖且有临床意义的改善。
  • 上述改善主要源于Vineland-II社交化和沟通分项的改善。
  • 巴洛伐普坦各剂量耐受良好,未发现药物相关安全性问题。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There are no approved pharmacological therapies to address the core symptoms of autism spectrum disorder (ASD), namely, persistent deficits in social communication and social interaction and the presence of restricted, repetitive patterns of behaviors, interests, or activities. The neuropeptide vasopressin has been implicated in the regulation of social behaviors, and its modulation has emerged as a therapeutic target for ASD. The phase 2 VANILLA clinical trial reported here evaluated balovaptan, an orally administered selective vasopressin V1a receptor antagonist, in 223 men with ASD and intelligence quotient ≥70. The drug was administered daily for 12 weeks and was compared with placebo. Participants were randomized to placebo (n = 75) or one of three balovaptan dose arms (1.5 mg, n = 32; 4 mg, n = 77; 10 mg, n = 39). Balovaptan treatment was not associated with a change from baseline compared with placebo at 12 weeks in the primary efficacy endpoint (Social Responsiveness Scale, 2nd Edition). However, dose-dependent and clinically meaningful improvements on the Vineland-II Adaptive Behavior Scales composite score were observed for participants treated with balovaptan 4 or 10 mg compared with placebo. This was driven principally by improvements in the Vineland-II socialization and communication scores. Balovaptan was well tolerated across all doses, and no drug-related safety concerns were identified. These results support further study of balovaptan as a potential treatment for the socialization and communication deficits in ASD.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Bolognani F, Del Valle Rubido M, Squassante L, et al. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Sci Transl Med. 2019. PMID: 31043521. doi:10.1126/scitranslmed.aat7838

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。